Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Open-Label, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of DMUC-4064A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer

Trial Profile

A Phase I, Open-Label, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of DMUC-4064A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 16 Mar 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs RG 7882 (Primary)
  • Indications Adenocarcinoma; Fallopian tube cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer
  • Focus Adverse reactions
  • Sponsors Genentech
  • Most Recent Events

    • 16 Mar 2019 Results assessing the pharmacokinetics of Dmuc4064a (anti-MUC16 thiomab drug conjugate; three PK analytes-antibody- conjugated MMAE (acMMAE), total antibody (tAb), and unconjugated MMAE)) in patients with platinum-resistant ovarian cancer, were presented at the 120th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
    • 20 Jun 2018 Status changed from active, no longer recruiting to completed.
    • 27 Oct 2017 Planned End Date changed from 30 Dec 2017 to 14 Apr 2018.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top